C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Characterizing Canine Lymphoma As a Potential Large Animal Model of Human Diffuse Large B-Cell Lymphoma
Kristy L. Richards,Alison A. Motsinger-Reif,Hsiao-Wei Chen,Yuri Fedoriw,Cheng Fan,Dahlia M. Nielsen,Rachael Thomas,Chris Smith,Sandeep S. Dave,Charles M. Perou,Matthew Breen,Steven E. Suter +11 more
TL;DR: Parts of canine B-cell lymphomas that resemble human DLBCL are defined, identifying molecular similarities that could allow dogs to be used as a representative model of hDLBCL.
Journal ArticleDOI
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study
TL;DR: In this paper , the authors used single cell RNA sequencing (scRNAseq) on the C3Tag genetically engineered mouse model that forms DCIS-like precursor lesions and for which many lesions progress into end-stage basal-like molecular subtype IDC.
Journal ArticleDOI
Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.
William Sikov,Charles M. Perou,Mehra Golshan,Deborah Collyar,Donald A. Berry,Olwen Hahn,Baljit Singh,Clifford A. Hudis,EP Winer +8 more
TL;DR: CALGB 40603 is designed to determine if the addition of carboplatin and/or bevacizumab to standard NAC raises the pCR rate from an estimated 35% to ≥55%.
Journal ArticleDOI
Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.
Aranzazu Fernandez-Martinez,Mattia Rediti,Gong Tang,Tomás Pascual,Katherine A. Hoadley,David Venet,Naim U. Rashid,Patricia A. Spears,Md N. Islam,Sarra El-Abed,Judith M Bliss,Matteo Lambertini,Jens Huober,David Goerlitz,Rong Hu,Peter C. Lucas,Sandra M. Swain,Christos Sotiriou,Charles M. Perou,Lisa A. Carey +19 more
TL;DR: In early-stage HER2+ breast cancer, the relationship between pCR and EFS differs by tumor intrinsic subtype, and the benefit of dual vs. single Her2-blockade seems to be limited to HER2-Enriched subtype tumors.
Journal ArticleDOI
Characterization of aggressive breast cancer in African American and Caucasian women: Patterns of gene expression in primary breast tumors
Rita Nanda,Zhiyuan Hu,Xiaping He,Maria Tretiakova,Tatyana A. Grushko,Francis Ikpatt,Charles M. Perou,O. I. Olopade +7 more
TL;DR: A large number of the patients in this study had no known history of breast cancer, and the once-in-a-lifetime check-up found that these patients were at high risk of developing breast cancer in the future.